NeuroOne Medical Technologies Corporation
Developer and manufacturer of flexible thin‑film intracranial electrode arrays and associated therapeutic hardware for invasive brain monitoring, mapping and radiofrequency ablation. Operates in‑house microfabrication and automated manufacturing for temporary intracranial depth and cortical electrode arrays, and provides an integrated sEEG‑guided radiofrequency ablation system with U.S. regulatory clearance for lesion creation. Leadership includes clinicians and engineers with academic and industry experience in translational neuroscience, neural engineering, materials science and medical device regulatory practice.
Industries
N/A
Nr. of Employees
small (1-50)
NeuroOne Medical Technologies Corporation
Products
Temporary intracranial depth electrode (sEEG)
Depth electrode intended for temporary (<30 days) subsurface brain recording, monitoring and stimulation with multiple contact count and spacing options and a disposable cable assembly.
Temporary cortical thin‑film strips and grids
Thin‑film cortical strip and grid electrodes for temporary surface recording, monitoring and stimulation with design elements aimed at reducing immune response and improving surgical handling.
sEEG‑integrated radiofrequency ablation system
Radiofrequency ablation system indicated for creation of radiofrequency lesions in nervous tissue and described as integrated with intracranial monitoring and mapping workflows to enable bedside ablation procedures.
Temporary intracranial depth electrode (sEEG)
Depth electrode intended for temporary (<30 days) subsurface brain recording, monitoring and stimulation with multiple contact count and spacing options and a disposable cable assembly.
Temporary cortical thin‑film strips and grids
Thin‑film cortical strip and grid electrodes for temporary surface recording, monitoring and stimulation with design elements aimed at reducing immune response and improving surgical handling.
sEEG‑integrated radiofrequency ablation system
Radiofrequency ablation system indicated for creation of radiofrequency lesions in nervous tissue and described as integrated with intracranial monitoring and mapping workflows to enable bedside ablation procedures.
Services
On‑site and remote clinical education, training and post‑deployment support for implantation and use of electrode and ablation systems.
Support for feasibility studies, preclinical and clinical evaluations, and conference/peer‑review dissemination.
On‑site and remote clinical education, training and post‑deployment support for implantation and use of electrode and ablation systems.
Support for feasibility studies, preclinical and clinical evaluations, and conference/peer‑review dissemination.
Expertise Areas
- Intracranial electrophysiology (iEEG/ECoG) and clinical mapping
- Thin‑film neural probe microfabrication and process engineering
- Preclinical feasibility and in vivo/ex vivo lesion characterization
- Radiofrequency ablation integrated with intracranial monitoring
Key Technologies
- Flexible thin‑film polyimide electrode arrays
- Stereotactic depth electrode (sEEG) systems
- Cortical strip and grid (ECoG) electrodes
- Electrocorticography arrays using silicon carbide
News & Updates
Earnings conference call for first quarter and fiscal 2025.
Virtual investor webinar.
Report of a hospital completing an ablation procedure using the company's sEEG‑guided radiofrequency ablation system.
Press reports covering regulatory submission and review activity for the sEEG‑guided radiofrequency ablation system.
Multiple reports of feasibility studies and preclinical evaluations for the sEEG‑guided radiofrequency ablation system.
Regulatory clearance from the U.S. Food and Drug Administration for a radiofrequency ablation system intended to create lesions in nervous tissue for functional neurosurgical procedures (K231675).
Earnings conference call for first quarter and fiscal 2025.
Virtual investor webinar.
Report of a hospital completing an ablation procedure using the company's sEEG‑guided radiofrequency ablation system.
Press reports covering regulatory submission and review activity for the sEEG‑guided radiofrequency ablation system.
Multiple reports of feasibility studies and preclinical evaluations for the sEEG‑guided radiofrequency ablation system.
Regulatory clearance from the U.S. Food and Drug Administration for a radiofrequency ablation system intended to create lesions in nervous tissue for functional neurosurgical procedures (K231675).